Objective: To assess the effects of dietary supplementation using two isomeric blends of conjugated linoleic acid (CLA) on immune function in healthy human volunteers. Design: Double-blind, randomised, placebo-controlled intervention trial. Subjects and intervention: A total of 55 healthy volunteers (n ¼ 20 males, n ¼ 35 females) were randomised into one of three study groups who received 3 g/day of a fatty acid blend containing a 50:50 cis-9, trans-11: trans-10, cis-12 CLA isomer blend (2 g CLA), and 80:20 cis-9, trans-11: trans-10, cis-12 (80:20) CLA isomer blend (1.76 g CLA) or linoleic acid (control, 2 g linoleic acid) for 8 weeks.Results: Supplementation with the 80:20 CLA isomer blend significantly (Pr0.05) enhanced PHA-induced lymphocyte proliferation. CLA decreased basal interleukin (IL)-2 secretion (Pr0.01) and increased PHA-induced IL-2 and tumor necrosis factor a (TNFa) production (Pr0.01). However, these effects were not solely attributable to CLA as similar results were observed with linoleic acid. CLA supplementation had no significant effect on peripheral blood mononuclear cells IL-4 production, or on serum-soluble intercellular adhesion molecule-1 (sICAM-1) or plasma prostaglandin E 2 (PGE 2 ) or leukotreine B 4 (LTB 4 ) concentrations.Conclusions: This study shows that CLA supplementation had a minimal effect on the markers of human immune function. Furthermore, supplementation with CLA had no immunological benefit compared with linoleic acid. Sponsorship: CLA supplements were provided by Loders Croklaan.